{"product_id":"celc-marketing-mix","title":"(CELC) Celcuity Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Celcuity Inc. 4P's Marketing Mix Analysis explains the company’s Product, Price, Place, and Promotion strategy and shows how its offerings are positioned and marketed; the page includes a real preview\/sample of the analysis so you can evaluate style and substance before buying—purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage oncology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity’s product is a clinical-stage oncology platform, not a mass-market drug, built to match therapy to the patient through biomarkers. Its lead program, gedatolisib, is in Phase 3 testing in HR+, HER2- breast cancer, a large precision-oncology market. The model targets biomarker-guided care, so value comes from better fit, not broad use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCELsignia live tumor-cell diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCELsignia live tumor-cell diagnostics tests a patient’s own live tumor cells to find the cellular dysfunction driving the cancer, so doctors can better match therapy to the biology. In Celcuity Inc.’s 4P mix, it supports a precision-medicine offer that is tied to treatment selection, not just testing volume. The platform is built for more targeted choices in cancers where one-size-fits-all care often misses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGedatolisib PI3K-mTOR inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGedatolisib is Celcuity Inc.'s selective PI3K-mTOR drug candidate for hormone receptor positive, HER2-negative advanced or metastatic breast cancer. It targets class I PI3K isoforms and mTOR, a pathway tied to tumor growth and resistance, and is in late-stage clinical development. In 2025, this niche still matters because HR+\/HER2-negative breast cancer is the largest breast cancer subtype and the main commercial focus for targeted therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCELsignia MP assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCELsignia MP is a qualitative lab-developed test that reads HER2, c-Met, and PI3K signaling in breast and ovarian tumor cells. It broadens Celcuity Inc.'s product mix beyond therapeutics and into diagnostics, which can support a wider commercial footprint. The test targets 2 tumor types and 3 key pathways, giving Celcuity a sharper place in precision oncology.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQualitative LDT for breast and ovarian tumors\u003c\/li\u003e\n\u003cli\u003eMeasures HER2, c-Met, and PI3K activity\u003c\/li\u003e\n\u003cli\u003eExpands Celcuity beyond drug-only revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePfizer-licensed development rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelcuity holds Pfizer-licensed development and commercialization rights for gedatolisib, a key product asset that ties its pipeline to a molecule first advanced by Pfizer. That external validation helps reduce scientific risk and strengthens the product story in oncology partnering. Celcuity is using this right to push gedatolisib through late-stage development, not just early lab work.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePfizer-origin asset\u003c\/li\u003e\n\u003cli\u003ePartner-backed validation\u003c\/li\u003e\n\u003cli\u003eSupports oncology commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCelcuity’s Precision Oncology Pairing: Late-Stage Drug Plus Diagnostic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. centers on precision oncology: gedatolisib, a Pfizer-origin PI3K-mTOR inhibitor, is in Phase 3 for HR+\/HER2- breast cancer, while CELsignia MP reads HER2, c-Met, and PI3K signaling in breast and ovarian tumor cells. The mix pairs a late-stage drug with a diagnostic platform, so value comes from matched treatment, not broad-volume sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003egedatolisib\u003c\/td\u003e\n\u003ctd\u003eHR+\/HER2- breast cancer\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCELsignia MP\u003c\/td\u003e\n\u003ctd\u003eBreast and ovarian tumors\u003c\/td\u003e\n\u003ctd\u003eLDT diagnostic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P’s analysis of Celcuity Inc.’s product, pricing, place, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Celcuity Inc.’s 4Ps into a quick, digestible view that eases strategic review and team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography linking each Celcuity claim to primary industry reports, datasets, and benchmarks to speed due diligence and build credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinneapolis headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. is headquartered in Minneapolis, Minnesota, and the site anchors its U.S. footprint. The corporate base supports research and development plus administrative work, helping coordinate clinical and business operations from one hub. For a biotech company, that central setup matters because it keeps teams close to decision-makers and speeds execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States patient focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. is focused on U.S. patients, so its first commercial path runs through domestic oncology centers. In 2025, the U.S. was projected to have about 316,950 new invasive breast cancer cases and 42,170 deaths, keeping demand concentrated in major cancer clinics. That makes U.S. referral networks and payer access the key gatekeepers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and laboratory channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCELsignia is placed through clinical and laboratory channels, not retail, because each test starts with a patient tumor sample and a lab readout. Access depends on physician referral, pathology handling, and specimen shipping, so the sales path is tied to oncology care centers and lab workflows. That makes reach slower than over-the-counter products, but it fits a high-touch test that needs clinical oversight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGedatolisib is aimed at advanced cancer care, so the main place of use is oncology treatment centers, hospital infusion units, and specialist cancer clinics. These settings already handle complex biologics, monitor side effects closely, and route patients through tumor boards and oncology networks.\u003c\/p\u003e\n\u003cp\u003eFor Celcuity Inc., distribution depends on regulatory approval and fast adoption by large cancer centers, since access usually starts with institutions that manage high-volume solid tumor care and then expands through referral networks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospital-based oncology care\u003c\/li\u003e\n\u003cli\u003eSpecialist cancer networks\u003c\/li\u003e\n\u003cli\u003eApproval first, adoption second\u003c\/li\u003e\n\u003cli\u003eBest fit: advanced cancer patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePfizer commercialization pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePfizer gives Celcuity a ready-made commercialization route for Gedatolisib, so the drug can reach market through a partner network instead of a small solo launch. That matters for market access, payer reach, and commercial scale, especially if Celcuity does not build a full sales force on its own. The deal also broadens potential geographic coverage beyond Celcuity’s base footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePfizer adds launch scale and reach.\u003c\/li\u003e\n\u003cli\u003eAccess can extend beyond Celcuity alone.\u003c\/li\u003e\n\u003cli\u003eCommercial terms support later market entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCelcuity’s Cancer-Center Launch Hinges on Partners and Payer Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. places Celsignia and gedatolisib in U.S. oncology care, not retail, so access starts in cancer centers, pathology labs, and hospital infusion units. Minneapolis is the operating base, but commercial reach depends on physician referral, specimen shipping, and payer approval. Pfizer expands gedatolisib reach beyond Celcuity’s own footprint.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. breast cancer\u003c\/td\u003e\n\u003ctd\u003e316,950 new cases, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare setting\u003c\/td\u003e\n\u003ctd\u003eOncology centers, labs, infusion units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch route\u003c\/td\u003e\n\u003ctd\u003ePfizer partner network\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCelcuity Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Celcuity Inc. 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete and ready to use, no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific platform messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity’s scientific platform messaging leans on precision oncology, positioning the Company around finding the specific pathway dysfunction driving each cancer case. That frame matters to clinicians and researchers because its lead program, gedatolisib, is being advanced in Phase 3 development for advanced breast cancer. For investors, the message ties the science to a clear pipeline focus and a single lead asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. uses clinical-trial visibility as its main promotion tool because it is a clinical-stage Company with no commercial product yet. Gedatolisib is in Phase 3 VIKTORIA-1, and CELsignia is still being advanced, so every update shows real development progress. These trial milestones help build awareness with investors and physicians and signal momentum across 2 lead programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. uses press releases to share pipeline milestones, licensing moves, and trial updates, with gedatolisib as its lead program. As a small biotech with no commercial product sales, these releases are a key way to keep investors aware of strategy and clinical progress. In 2025, the company’s public updates remained centered on research and development, not revenue generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor relations and SEC filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelcuity uses SEC filings and investor materials, mainly 10-K, 10-Q, and 8-K reports, to show trial progress, cash use, and business updates. For a public biotech, this is a core promotion channel because it reaches 3 key groups: shareholders, analysts, and potential partners. In 2025-2026, this disclosure flow stays central as investors track clinical milestones and funding needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10-K, 10-Q, and 8-K updates\u003c\/li\u003e\n\u003cli\u003eShows trial and cash progress\u003c\/li\u003e\n\u003cli\u003eReaches 3 audience groups\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical and scientific outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelcuity Inc. leans on medical and scientific outreach because its core audience is oncologists, researchers, and trial sites. The clearest example is its Phase 3 VIKTORIA-1 study of gedatolisib, which is enrolling 354 patients, so data sharing is the main promotion tool for adoption and partner interest.\u003c\/p\u003e\n\u003cp\u003eThat means peer-reviewed results, congress updates, and investigator engagement matter more than broad consumer ads. In this segment, credibility drives the funnel: strong clinical data can move prescribers and collaborators faster than brand messaging alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary audience: clinical decision-makers\u003c\/li\u003e\n\u003cli\u003ePromotion: data, not mass advertising\u003c\/li\u003e\n\u003cli\u003eGoal: adoption and partnership interest\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCelcuity’s 2025-26 Promotion: Clinical Data Over Mass Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. promotes itself through clinical data, SEC filings, and investor releases, not mass ads, because it is still a clinical-stage Company. In 2025-2026, promotion centers on gedatolisib, now in Phase 3 VIKTORIA-1 with 354 patients, plus CELsignia updates. The goal is simple: build trust with doctors, analysts, and partners.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePress releases\u003c\/td\u003e\n\u003ctd\u003eTrial and pipeline news\u003c\/td\u003e\n\u003ctd\u003e2 lead programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC filings\u003c\/td\u003e\n\u003ctd\u003eCash and progress\u003c\/td\u003e\n\u003ctd\u003e10-K, 10-Q, 8-K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific outreach\u003c\/td\u003e\n\u003ctd\u003eClinician trust\u003c\/td\u003e\n\u003ctd\u003eVIKTORIA-1: 354 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo commercial list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. has no commercial list price yet because it is still clinical-stage. Gedatolisib is not a broadly marketed medicine, so pricing will only be set after approval and payer reimbursement. As of its latest public filings, Celcuity still reported no product revenue, which means the price remains undisclosed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic reimbursement pending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCELsignia MP pricing is still tied to payer reimbursement, so the real price signal is market access, not list price. For a lab-developed test, coding, coverage, and prior payer acceptance can decide whether it gets used at all.\u003c\/p\u003e\n\u003cp\u003eThat matters because payers often delay or deny payment until clinical utility is clear. If reimbursement is weak, Celcuity Inc. may need to price conservatively to drive adoption.\u003c\/p\u003e\n\u003cp\u003eSo, diagnostic reimbursement pending keeps the price lever flexible but uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelopment-stage value model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc.’s price case is a development-stage value model: value comes from gedatolisib pipeline odds, not product sales, because the Company still has no commercial revenue. Its pricing power is indirect, tied to Phase 3 data, regulatory approval, and future reimbursement, which is standard for biotech before launch. In this setup, a single clinical win can re-rate the stock fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePfizer economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePfizer’s license means Gedatolisib economics are set by partnership terms, not a direct retail price. That usually means royalties, milestone payments, and shared launch costs, which can lift Celcuity Inc. margins if sales scale. It also lowers near-term pressure to define end-customer pricing before approval and launch.\u003c\/p\u003e\n\u003cp\u003eIn practice, the deal structure shapes net revenue more than list price, so commercial leverage depends on trial success and contract terms. For investors, the key watch item is how much of future sales Celcuity keeps after Pfizer-linked economics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalties can reduce gross-to-net.\u003c\/li\u003e\n\u003cli\u003eMilestones support near-term cash.\u003c\/li\u003e\n\u003cli\u003ePricing is set after launch.\u003c\/li\u003e\n\u003cli\u003eNet economics matter most.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty oncology economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf approved, Gedatolisib would likely be priced like a specialty oncology therapy, often set around clinical benefit and narrow use. In the U.S., many branded cancer drugs launch above $100,000 a year, while Medicare Part D out-of-pocket is capped at $2,000 in 2025. Final net price would still depend on payer rebates, competition, and coverage rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty oncology pricing is benefit-driven.\u003c\/li\u003e\n\u003cli\u003eLaunch prices often exceed $100,000 yearly.\u003c\/li\u003e\n\u003cli\u003eRebates can cut net realized price.\u003c\/li\u003e\n\u003cli\u003eCoverage terms shape access and uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCelcuity Pricing Hinges on FDA Approval and Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCelcuity Inc. has no commercial price yet for gedatolisib, so price is still a post-approval issue tied to trial success, FDA review, and payer coverage. CELsignia MP is also reimbursement-driven, so market access matters more than list price. If approved, oncology pricing would likely follow specialty-drug norms, with net price shaped by rebates and coverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eLatest signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGedatolisib\u003c\/td\u003e\n\u003ctd\u003eNo list price; not marketed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCELsignia MP\u003c\/td\u003e\n\u003ctd\u003ePrice depends on reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cancer drug context\u003c\/td\u003e\n\u003ctd\u003eOften above $100,000 yearly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D OOP cap\u003c\/td\u003e\n\u003ctd\u003e$2,000 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234249318665,"sku":"celc-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/celc-marketing-mix.webp?v=1785714568","url":"https:\/\/dcfanalyst.com\/products\/celc-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}